论文部分内容阅读
目的:探究调强放疗(IMRT)联合厄洛替尼治疗晚期食管癌的疗效和安全性,为临床晚期食管癌的治疗提供参考。方法:选择晚期食管癌患者87例作为研究对象,对照组41例采用单纯IMRT,试验组46例采用IMRT配合厄洛替尼治疗,观察分析两组患者的临床疗效和不良反应发生情况,并随访第1、2年的生存状况。结果:试验组患者有效率(86.96%)明显高于对照组(43.90%)(χ2=18.083,P<0.05),放射性食管炎、口腔黏膜炎、放射性肺炎、骨髓抑制、消化道反应等不良反应发生率两组间差异均有统计学意义(P<0.05),虽然第1、2年的生存率对照组(68.29%、48.78%)略高于试验组(65.22%、47.83%),但两组间生存状况的差异无统计学意义(χ2=0.092、χ2=0.008,P=0.761、P=0.929)。结论:调强放疗联合厄洛替尼对晚期食管癌治疗效果显著,且并发症少,临床可以作为晚期食管癌治疗的一种参考方法。
Objective: To investigate the efficacy and safety of IMRT combined with erlotinib in the treatment of advanced esophageal cancer, and provide a reference for the treatment of advanced esophageal cancer. Methods: Totally 87 patients with advanced esophageal cancer were enrolled. 41 patients in the control group were treated with IMRT alone. 46 patients in the control group were treated with IMRT and erlotinib. The clinical efficacy and adverse reactions of the two groups were observed and followed up The first two years of living conditions. Results: The effective rate (86.96%) in the experimental group was significantly higher than that in the control group (43.90%) (χ2 = 18.083, P <0.05), and radioactive esophagitis, oral mucositis, radiation pneumonitis, myelosuppression and gastrointestinal reactions The difference between the two groups was statistically significant (P <0.05). Although the survival rates of the first and second years in the control group (68.29%, 48.78%) were slightly higher than those in the experimental group (65.22%, 47.83%), There was no significant difference in survival between groups (χ2 = 0.092, χ2 = 0.008, P = 0.761, P = 0.929). Conclusion: IMRT combined with erlotinib has a significant effect on the treatment of advanced esophageal cancer with fewer complications, and can be used as a reference for the treatment of advanced esophageal cancer.